Following the healthcare company’s FY 18 results, CSL’s Chief Financial Officer David Lamont and nabtrade’s Customer Insights Manager Vishal Teckchandani discuss:
- Data insights on how nabtrade customers are investing in CSL,
- Why investors should focus on the company's research & development activities,
- If CSL has an appetite for a stock split, and
- The CSL-112 trial, which is the largest trial undertaken by CSL for individuals who have suffered a heart attack.
Note: The article referred to in the video can be viewed here.